These findings, along with other smaller studies, led to treatment guidelines that do not recommend administration of chemotherapy for patients with very low-risk HR + /HER2- early breast cancer, and endorse use of adjuvant chemotherapy for the high-risk group29,41,50. The gene discussed is ERBB2; the disease is breast cancer.